Skip to content
Screener

Emergent Biosolutions EBS MCM Products — Total revenues

Other segment segments

Commercial Products
$52.4M-22.4%

Similar metrics at other companies

Quanterix Corporation logo
QTRXProduct revenue — Total revenues
$23.48M+39.5%
Cactus logo
WHDProduct revenue — Total revenues
$297.24M+42.2%
Kinetik Holdings logo
KNTKProduct revenue — Total revenues
$312.23M-0.1%
TBR
TBRGRCM services — Total revenues
$39.82M-6.1%
Artivion logo
AORTProducts — Total revenues
$99.91M+14.3%
Flotek Industries logo
FTKProducts — Total revenues
$84.2M+57.7%

Other financials

Income statement

See full
Revenue$234.3M+66.3%
Gross profit$137.2M+85.4%
Operating income-$125.1M-7,919%
Net income-$180.2M-1,402%
EPS (diluted)-$3.49-1,486%

Balance sheet

See full
Cash & equivalents$140.9M-48.0%
Total debt$588.2M-13.0%
Total equity$341.4M-36.3%
Total assets$1.1B-21.2%

Cash flow

See full
Operating cash flow$56.1M-47.3%
CapEx$2.1M-27.6%
Free cash flow$54.0M-47.8%

Valuation

See full
Market cap$248.16M-43.0%
Enterprise value$695.46M-17.3%
P/S0.3×-0.2×

Profitability

See full
Gross margin55.9%+2.4pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin11.9%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.7×+0.5×
Current ratio5.4×-0.2×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.

Filed
Aug 5, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001367644-26-000082
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenues reportable segments:
Commercial Products$52.4$67.5$95.3$112.8
MCM Products168.058.4269.8215.0
Reconciliation of revenue:220.4125.9365.1327.8
All other revenues (1)13.915.025.335.3
Total revenues$234.3$140.9$390.4$363.1
Cost of sales reportable segments:
Commercial Products (2)$36.2$36.2$63.0$60.7

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Emergent Biosolutions's MCM products — total revenues?
Emergent Biosolutions (EBS) reported MCM products — total revenues of $168M in Q2 2026.
How has Emergent Biosolutions's MCM products — total revenues changed year-over-year?
Emergent Biosolutions's MCM products — total revenues increased by 187.7% year-over-year, from $58.4M to $168M.
What is the long-term trend for Emergent Biosolutions's MCM products — total revenues?
Over 4 years (2021 to 2025), Emergent Biosolutions's MCM products — total revenues has grown at a -6.0% compound annual growth rate (CAGR), from $585.9M to $456.7M.
What does MCM products — total revenues mean?
This represents the total gross income generated by the Medical Countermeasures (MCM) Products segment from the sale of goods and services. It serves as a primary indicator of the segment's market demand and revenue-generating capacity within the company's portfolio.

Ask your AI about Emergent Biosolutions's mcm products — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude